MP49-10 DIFFERENTIAL EXPRESSION OF MICRORNA PROFILES IN PROSTATE CANCER SPECIMENS: A VALIDATION STUDY (2014)

You have accessJournal of UrologyProstate Cancer: Basic Research IV1 Apr 2014MP49-10 DIFFERENTIAL EXPRESSION OF MICRORNA PROFILES IN PROSTATE CANCER SPECIMENS: A VALIDATION STUDY Nikhil Waingankar, Nicholas Broccoli, Soroush Rais-Bahrami, Kevin Smith, Michaela Oswald, Houman Khalili, Annette Lee, Theresa Chan, Oksana Yaskiv, Peter Gregersen, and Manish Vira Nikhil WaingankarNikhil Waingankar More articles by this author , Nicholas BroccoliNicholas Broccoli More articles by this author , Soroush Rais-BahramiSoroush Rais-Bahrami More articles by this author , Kevin SmithKevin Smith More articles by this author , Michaela OswaldMichaela Oswald More articles by this author , Houman KhaliliHouman Khalili More articles by this author , Annette LeeAnnette Lee More articles by this author , Theresa ChanTheresa Chan More articles by this author , Oksana YaskivOksana Yaskiv More articles by this author , Peter GregersenPeter Gregersen More articles by this author , and Manish ViraManish Vira More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1111AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives MicroRNAs (miRNA) are small, noncoding nucleic acids that regulate gene expression. Altered miRNA expression may be a factor in carcinogenesis. We previously found 27 miRNA with differential expression that varied at least two-fold between benign and cancerous prostate glands in 64 patients. The goal of this study was to validate these findings in a selected group. Methods 29 patients were selected: five each had organ-confined Gleason 3+3, 3+4, 4+3, and 4+4 or higher disease. The remaining nine patients had development of metastatic disease. RNA was extracted from prostate cancer foci and areas of benign glands from paraffin embedded prostatectomy specimens. Expression profiles for 577 miRNA were analyzed using Taqman OpenArray. Data analysis was performed using the mean-centering method for normalizing miRNA across the original and validation cohorts. Results Significant overlap was found between the original and validation cohorts for miRNA that were upregulated at least two-fold between benign and cancerous glands (Figure 1, p<0.05). Two miRNA were downregulated that overlap with the original set (Figure 2, p<0.05). There were no differences in miRNA expression between T2 and T3 cases. Comparison of Gleason 6 vs Gleason 8+ showed significant difference in expression of mir-185, mir106b, and mir-181a. Overexpression of mir-21 was seen in the benign glands of the metastatic subset compared to benign glands of those with localized disease. Conclusions This study validates our findings on differential expression of miRNA between cancerous and benign glands. There was a significant difference in expression between Gleason 6 and 8 cancers, and no differences were found between T2 and T3. Mir-21, a known oncomir that is overexpressed in other metastatic tumors, may represent a unique signature in the benign glands of patients with metastatic prostate cancer. With further study, miRNA may have prognostic utility or may guide risk stratification in the future. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e505-e506 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Nikhil Waingankar More articles by this author Nicholas Broccoli More articles by this author Soroush Rais-Bahrami More articles by this author Kevin Smith More articles by this author Michaela Oswald More articles by this author Houman Khalili More articles by this author Annette Lee More articles by this author Theresa Chan More articles by this author Oksana Yaskiv More articles by this author Peter Gregersen More articles by this author Manish Vira More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...